How Testosterone Cypionate Affects HDL Cholesterol

Once the cypionate ester is cleaved the hormone is testosterone, so the HDL mechanism is the same as for any injectable testosterone ester:

1. Hepatic triglyceride lipase upregulation: Androgen receptor signalling at the hepatocyte increases HTGL activity, and HTGL catabolises HDL particles. Thompson (1989, PMID 2915439) measured a 25% rise in postheparin HTGL activity on 200 mg/week of intramuscular testosterone enanthate, a change that did not reach statistical significance, compared with a 123% rise on oral stanozolol at 6 mg/day. Injectable testosterone produces a genuine but comparatively mild hepatic lipase signal.

2. ApoA-I reduction: Thompson measured apoA-I falling 8% on testosterone versus 40% on stanozolol. ApoA-I is the structural protein of HDL particles, so fewer of them means fewer particles can be maintained.

3. Oestradiol partially protects, and removing it hurts: Zmuda (1993, PMID 8487666) gave weightlifters testosterone enanthate alone and testosterone plus an aromatase inhibitor. With aromatisation blocked, HDL fell 20% rather than 16%, apoA-I fell 15% rather than 12%, and HTGL activity rose 38% rather than 21%. Oestradiol suppresses hepatic lipase, and testosterone funds that protection through its own aromatisation.

4. HDL3 rather than HDL2: Thompson found the fall on testosterone was confined to the HDL3 subfraction, whereas oral stanozolol destroyed HDL2 by 71%. HDL2 performs most of the cardioprotective reverse cholesterol transport, so the subfraction pattern on injectable testosterone is meaningfully less damaging than the total percentage suggests.

Cypionate versus enanthate: no difference. The ester does not reach the hepatocyte as an intact molecule.

Replacement doses (100-200 mg/week):

• HDL typically falls 10 to 20%
• Whitsel (2001, PMID 11566455) pooled 19 studies in 272 hypogonadal men on an average of 179 mg of intramuscular testosterone ester every 16 days and found HDL down 4 mg/dL, alongside total cholesterol down 14 mg/dL and LDL down 5 mg/dL
• Thompson (1989, PMID 2915439) measured HDL down 9% on 200 mg/week in trained men

Supraphysiological doses (300-600+ mg/week):

• HDL falls 20 to 40%
• Bhasin (2001, PMID 11701431) found HDL changes negatively correlated with testosterone concentration in a linear dose-response relationship up to 600 mg/week. There is no dose at which the effect stops worsening.

With an aromatase inhibitor: add roughly a quarter again to the expected fall, based on the Zmuda comparison.

In stacks: HDL suppression compounds. Webb (1984, PMID 6493049) documented HDL of 29 mg/dL on cycle versus 61 mg/dL off in bodybuilders using an oral plus testosterone plus nandrolone.

Timing: Measurable within 2 to 3 weeks, plateau by week 6 to 8. Recovers over 6 to 12 weeks after stopping.

Baseline lipid panel before starting, including HDL, LDL, total cholesterol and triglycerides. ApoB if available.

On protocol:

• Recheck 8 to 12 weeks after starting or after any dose change.
• Annually once stable, and sooner after starting or increasing an aromatase inhibitor.

What to watch:

• HDL below 1.0 mmol/L (roughly 40 mg/dL) in men is the conventional threshold for concern.
• HDL below 0.8 mmol/L (roughly 30 mg/dL) on a replacement dose suggests something else is contributing: an oral in the stack, an over-suppressed oestradiol, or a supraphysiological dose.
• Track the LDL to HDL ratio and non-HDL cholesterol, which capture both sides of the picture in one number.

Attribution: if HDL is in the twenties, look for an oral 17-alpha-alkylated compound before blaming the testosterone.

Dose is the primary lever: the dose-response is linear, so a 25% dose reduction produces a proportional benefit.

Do not over-suppress oestradiol: This is the single most avoidable cause of a worse HDL on testosterone, and it is well documented experimentally.

Cardiovascular exercise: 30 to 45 minutes, 4 to 5 times per week. This is the intervention with the strongest evidence for raising HDL and it works through a pathway testosterone does not touch.

Supplements, ranked honestly:

• Omega-3 at 3 to 4 g/day EPA and DHA: strong for triglycerides, minimal for HDL
• Niacin raises HDL but has not shown outcome benefit in trials and has real side effects
• Citrus bergamot 500 to 1000 mg/day has modest human evidence, none of it in androgen users

Perspective: a 10 to 20% HDL fall at replacement doses is expected and is not, on its own, a reason to stop testosterone therapy. A fall into the twenties is a different conversation and usually has a second cause.

Further reading: Cholesterol supplements on cycle, ranked by evidence